PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.